Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights Novo Nordisk, Toyota Motor, Salesforce, Abbott Laboratories, Raytheon Technologies, and Equinor

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 10, 2022 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S (NVO - Free Report) , Toyota Motor Corp. (TM - Free Report) , Salesforce, Inc. (CRM - Free Report) , Abbott Laboratories (ABT - Free Report) ,Raytheon Technologies Corporation (RTX - Free Report) , and Equinor ASA (EQNR - Free Report) .

Here are highlights from Thursday’s Analyst Blog:

Top Research Reports for Novo Nordisk, Toyota and

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Toyota Motor Corp., and Salesforce, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>

Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+36.9% vs. +19.3%) on the back of the company's promising diabetes drug, Ozempic, which is off to a solid start since its launch. The launch of Rybelsus also looks impressive. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs is expected to boost sales.

However, lower realized prices in the United States, loss of exclusivity for products and stiff competition affect sales. Also, sales are being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy have hurt the stock. The patent expiry on some of the products in Novo Nordisk's portfolio is a concern.

(You can read the full research report on Novo Nordisk here >>>)

Toyota shares have declined -7.0% over the past year against the Zacks Automotive - Foreign industry's decline of -27.3%. The Zacks analyst believes that the company is also reeling under severe chip crunch compounded by the Russia-Ukraine war. The Japanese auto biggie has warned of unprecedented commodity inflation. It expects a sharp increase in material costs to adversely impact the fiscal 2023 income to the tune of ¥1.45 trillion. Supply-chain disruptions, tough labor market, logistical challenges and manufacturing inefficiencies will play spoilsports.

In the light of such headwinds, the company expects its operating income to decline around 20% on a year-over-year basis in fiscal 2023. High Capex and R&D expenses on advanced technologies are also likely to dent near-term margins and cash flows of the company. Further, Toyota's rising debt levels play a spoilsport. Consequently, the stock warrants a bearish stance now.

(You can read the full research report on Toyota here >>>)

Salesforce shares have declined -25.7% over the year-to-date basis against the Zacks Computer - Software industry's decline of -21.1%. The Zacks analyst believes the stiff competition faced by the company is a concern. Besides, unfavorable currency fluctuations along with increasing investments in international expansions and data centers are an overhang on near-term profitability. Nevertheless, Salesforce is benefiting from a robust demand environment as customers are undergoing a major digital transformation.

The rapid adoption of its cloud-based solutions is driving demand for its products. Salesforce's sustained focus on introducing more aligned products as per customer needs is driving its top-line. Continued deal wins in the international market is another growth driver. Furthermore, the recent acquisition of Slack would position the company to be a leader in the enterprise team collaboration solution space and better compete with Microsoft's Teams product.

(You can read the full research report on Salesforce here >>>)

Other noteworthy reports we are featuring today include Abbott Laboratories, Raytheon Technologies Corporation, and Equinor.

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                               

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.